Compare Vanguard International High Dividend Yield ETF (VYMI) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard International High Dividend Yield ETF vs 22nd Century Group Inc — how do they compare? Vanguard International High Dividend Yield ETF trades at $100.7 (market cap $22.80B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 36675.4× 22nd Century Group Inc's market cap, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard International High Dividend Yield ETF for 50 Days and 22nd Century Group Inc for 32 Days on average.
| VYMI | XXII | |
|---|---|---|
Market Cap | $22.80B | $621.67K |
Volume | 748,441 | 45,625 |
Sector | Broad Market / Factor | Consumer Staples |
52-Week High | $107.13 | $483.00 |
52-Week Low | $82.92 | $0.80 |
Typical Hold Time | 50 Days | 32 Days |
Enterprise Value | — | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VYMI trades at $100.53 with a slight 0.3% daily gain, though technical indicators signal bearish momentum with moving averages showing 11 sell signals versus 2 buy signals. The ETF's recent performance includes a 29% one-year return and 14.13% five-year average annual return, with strong institutional interest as firms like Envestnet increased holdings by 22% in Q2 2026. A dividend of $0.82 is scheduled for payment on September 22, 2026.
The outlook for VYMI is mixed; bullish sentiment from Seeking Alpha highlights sector catalysts in financials, energy, and healthcare supporting dividend growth, while technical bearishness and Fed rate hike impacts pose risks. Investors may find value in its 3.61% dividend yield and global diversification, but should monitor financials exposure (43.6% of holdings) amid rising rates.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
